Palmitoyl Tripeptide-1
INCI: Palmitoyl Tripeptide-1
Also known as: Pal-GHK, Biopeptide CL
PeptidespeptidesyntheticModerate evidencePregnancy safe
79
Skinlumis Rating
Comedogenic
0/5
Irritancy
0/5
Best applied
Both
Effective range
2%–5%
How It Works
A signal peptide that mimics GHK to upregulate dermal matrix proteins, with a lipid tail for skin penetration.
Palmitoyl tail enhances stratum corneum penetration; once cleaved, GHK signals fibroblast collagen and GAG synthesis.
pH Range
5.0–7.0
Benefits
- Boosts collagen
- Improves firmness
- Reduces fine lines
- Pairs well in dermal repair stacks
Proven For
What the evidence supports.
Fine linesLoss of firmness
Best For
- All skin types
Avoid If
No notable contraindications reported.
Layering Order
5/10
Mid-routine serum or treatment step.
Max Safe Concentration
5%
Concentration range in well-formulated products: 2%–5%
Seasonal Use
Year-round.
For Estheticians & Professionals
Half of the Matrixyl 3000 complex; sometimes sold solo as Biopeptide CL.
Clinical Evidence
The research behind Palmitoyl Tripeptide-1.
Every claim on this page traces to published research. Findings below are drawn from randomized trials and systematic reviews, each links to the study on PubMed.
Systematic Review
Oral collagen peptides at 2.5-10g daily significantly improved skin elasticity and reduced wrinkle depth after 8-12 weeks across 11 RCTs.
Choi FD, Sung CT, Juhasz MLW, Mesinkovska NA
Journal of Drugs in Dermatology, 2019
View Study →Journal of Drugs in Dermatology, 2019
Systematic Review
Estrogen deficiency following menopause causes 30% reduction in skin collagen within the first 5 years.
Wilkinson HN, Hardman MJ
Maturitas, 2017
View Study →Maturitas, 2017
Systematic Review
Chronic psychological stress elevates cortisol, accelerating skin aging through collagen degradation and barrier disruption.
Chen Y, Lyga J
Inflammation and Allergy Drug Targets, 2014
View Study →Inflammation and Allergy Drug Targets, 2014
Randomized Controlled Trial
Daily sunscreen use reduced photoaging markers by 24% over 4.5 years compared to discretionary use.
Hughes MCB, Williams GM, Baker P, Green AC
Annals of Internal Medicine, 2013
View Study →Annals of Internal Medicine, 2013
Pairs Well With
Conflicts With
No flagged conflicts. Still, patch-test new actives.
Your Skin Compatibility
Sign up to see how Palmitoyl Tripeptide-1 fits your skin archetype and personalised protocol.